Rabu et al. had designed SLPs generated from MELOE-1 melanoma antigen comprising class I and class II epitopes separated by an artificial cathepsin-sensitive linker (LLSVGG), which led to a major impact on the presentation of the CD4+ and CD8+ T cell epitopes [49]. The gene discussed is CD8A; the disease is melanoma.